Targeting genetic changes in lung adenocarcinoma
Lung Adenocarcinoma: From Genome Alterations to Therapeutic Discovery
Looking at genetic changes in lung adenocarcinoma to find new targeted treatments for people with this cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11131217 on NIH RePORTER |
What this research studies
Researchers analyze the DNA of lung adenocarcinoma tumors from patients to find the mutations that drive the cancer. They follow up key findings in the lab using cellular and animal models to understand how specific genes (like BRAF, EGFR, SOS1, MGA, and ADAR) or duplicated regulatory elements promote tumor growth. The team also builds genomically engineered models of aneuploidy to mimic patient tumors and test potential therapeutic approaches. Results aim to improve diagnostic markers and point to drug targets that could be tested in future clinical trials.
Who could benefit from this research
Good fit: People diagnosed with lung adenocarcinoma—especially those having their tumor genetically sequenced or with recurrent/metastatic disease—are the most relevant candidates for related clinical opportunities.
Not a fit: People without lung adenocarcinoma or whose tumors lack relevant genetic alterations may not directly benefit from this research.
Why it matters
Potential benefit: If successful, this work could lead to more precise treatments matched to the genetic patterns in a patient's tumor.
How similar studies have performed: Prior genomic discoveries such as EGFR and BRAF mutations have successfully led to targeted therapies, and this work builds on those proven approaches.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Meyerson, Matthew L. — Dana-Farber Cancer Inst
- Study coordinator: Meyerson, Matthew L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.